Literature DB >> 23269530

Targeted prophylaxis in cancer: the evidence accumulates.

Alok A Khorana.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23269530     DOI： 10.1007/s11739-012-0883-9

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  7 in total

1.  A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score.

Authors:  Melina Verso; Giancarlo Agnelli; Sandro Barni; Giampietro Gasparini; Roberto LaBianca
Journal:  Intern Emerg Med       Date:  2012-05-01       Impact factor: 3.397

2.  High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis.

Authors:  Russell A Moore; Nelly Adel; Elyn Riedel; Manisha Bhutani; Darren R Feldman; Nour Elise Tabbara; Gerald Soff; Rekha Parameswaran; Hani Hassoun
Journal:  J Clin Oncol       Date:  2011-08-01       Impact factor: 44.544

3.  Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer.

Authors:  A Maraveyas; J Waters; R Roy; D Fyfe; D Propper; F Lofts; J Sgouros; E Gardiner; K Wedgwood; C Ettelaie; G Bozas
Journal:  Eur J Cancer       Date:  2011-11-17       Impact factor: 9.162

Review 4.  Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis.

Authors:  Eitan Amir; Bostjan Seruga; Saroj Niraula; Lindsay Carlsson; Alberto Ocaña
Journal:  J Natl Cancer Inst       Date:  2011-07-09       Impact factor: 13.506

5.  Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer.

Authors:  Giancarlo Agnelli; Daniel J George; Ajay K Kakkar; William Fisher; Michael R Lassen; Patrick Mismetti; Patrick Mouret; Umesh Chaudhari; Francesca Lawson; Alexander G G Turpie
Journal:  N Engl J Med       Date:  2012-02-16       Impact factor: 91.245

6.  Development and validation of a predictive model for chemotherapy-associated thrombosis.

Authors:  Alok A Khorana; Nicole M Kuderer; Eva Culakova; Gary H Lyman; Charles W Francis
Journal:  Blood       Date:  2008-01-23       Impact factor: 22.113

7.  Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study.

Authors:  Giancarlo Agnelli; Gualberto Gussoni; Carlo Bianchini; Melina Verso; Mario Mandalà; Luigi Cavanna; Sandro Barni; Roberto Labianca; Franco Buzzi; Giovanni Scambia; Rodolfo Passalacqua; Sergio Ricci; Giampietro Gasparini; Vito Lorusso; Erminio Bonizzoni; Maurizio Tonato
Journal:  Lancet Oncol       Date:  2009-08-31       Impact factor: 41.316
  7 in total
  6 in total

1.  Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis.

Authors:  Floris T M Bosch; Frits I Mulder; Pieter Willem Kamphuisen; Saskia Middeldorp; Patrick M Bossuyt; Harry R Büller; Nick van Es
Journal:  Blood Adv       Date:  2020-10-27

2.  Cardiovascular oncology: a new discipline inside internal medicine?

Authors:  Domenico Prisco; Mario Milco D'Elios; Caterina Cenci; Lucia Ciucciarelli; Carlo Tamburini
Journal:  Intern Emerg Med       Date:  2014-03-19       Impact factor: 3.397

Review 3.  What is the Best Treatment for a Cancer Patient with Thrombosis?

Authors:  Miguel Barbosa
Journal:  Clin Med Insights Oncol       Date:  2014-05-01

Review 4.  Cancer-associated thrombosis: an overview.

Authors:  Ghaleb Elyamany; Ali Mattar Alzahrani; Eman Bukhary
Journal:  Clin Med Insights Oncol       Date:  2014-12-04

5.  Low antithrombin levels are associated with low risk of cardiovascular death but are a risk factor for cancer mortality.

Authors:  Licia Iacoviello; Romy de Laat-Kremers; Simona Costanzo; Qiuting Yan; Augusto Di Castelnuovo; Lisa van der Vorm; Amalia De Curtis; Marisa Ninivaggi; Chiara Cerletti; Maria Benedetta Donati; Bas de Laat
Journal:  PLoS One       Date:  2022-09-19       Impact factor: 3.752

Review 6.  The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer.

Authors:  Chanukya K Colonne; Emmanuel J Favaloro; Leonardo Pasalic
Journal:  Healthcare (Basel)       Date:  2022-03-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.